Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
HBM Holdings Ltd. ( (HK:2142) ) just unveiled an update.
HBM Holdings Ltd. has announced a strategic collaboration with AstraZeneca, which includes a share subscription agreement and a partnership to develop next-generation multi-specific antibodies. The agreement will see AstraZeneca subscribe to 9.15% of HBM’s shares, raising approximately US$105.3 million for HBM’s research and development and operational needs. The collaboration is expected to enhance HBM’s position in the biopharmaceutical industry by leveraging AstraZeneca’s global drug development expertise, potentially leading to significant advancements in antibody therapeutics. This partnership also involves establishing an innovation center in Beijing and could result in up to US$4.4 billion in milestone payments for HBM, underscoring the potential impact on the company’s growth and market presence.
More about HBM Holdings Ltd.
HBM Holdings Ltd. is a leading biopharmaceutical company in China, focusing on the development of next-generation multi-specific biologics. The company is dedicated to advancing innovative therapies in immunology and oncology, aiming to address high unmet medical needs.
YTD Price Performance: 362.37%
Average Trading Volume: 9,098,015
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$6.52B
See more data about 2142 stock on TipRanks’ Stock Analysis page.